BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

986 related articles for article (PubMed ID: 19101233)

  • 1. Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT; Nikolaou M; Birmpa D; Farmakis D; Paraskevaidis I; Bistola V; Katsoulas T; Filippatos G; Kremastinos DT
    Am J Cardiol; 2009 Jan; 103(1):73-5. PubMed ID: 19101233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.
    Nishii M; Inomata T; Takehana H; Naruke T; Yanagisawa T; Moriguchi M; Takeda S; Izumi T
    J Am Coll Cardiol; 2008 Jun; 51(24):2329-35. PubMed ID: 18549918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure.
    Isnard R; Pousset F; Chafirovskaïa O; Carayon A; Hulot JS; Thomas D; Komajda M
    Am Heart J; 2003 Oct; 146(4):729-35. PubMed ID: 14564330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function.
    Valle R; Aspromonte N; Feola M; Milli M; Canali C; Giovinazzo P; Carbonieri E; Ceci V; Cerisano S; Barro S; Milani L
    J Card Fail; 2005 Sep; 11(7):498-503. PubMed ID: 16198244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.
    Richards M; Nicholls MG; Espiner EA; Lainchbury JG; Troughton RW; Elliott J; Frampton CM; Crozier IG; Yandle TG; Doughty R; MacMahon S; Sharpe N; ;
    J Am Coll Cardiol; 2006 Jan; 47(1):52-60. PubMed ID: 16386664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification.
    Faggiano P; Valle R; Aspromonte N; D'Aloia A; Di Tano G; Barro S; Giovinazzo P; Milani L; Lorusso R; Dei Cas L
    Int J Cardiol; 2010 Apr; 140(1):88-94. PubMed ID: 19321212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-type natriuretic peptide levels in obese patients with advanced heart failure.
    Horwich TB; Hamilton MA; Fonarow GC
    J Am Coll Cardiol; 2006 Jan; 47(1):85-90. PubMed ID: 16386669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between CD4+ T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Fukunaga T; Soejima H; Irie A; Sugamura K; Oe Y; Tanaka T; Nagayoshi Y; Kaikita K; Sugiyama S; Yoshimura M; Nishimura Y; Ogawa H
    Am J Cardiol; 2007 Aug; 100(3):483-8. PubMed ID: 17659933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy.
    Schenk S; McCarthy PM; Starling RC; Hoercher KJ; Hail MD; Ootaki Y; Francis GS; Doi K; Young JB; Fukamachi K
    J Thorac Cardiovasc Surg; 2004 Jul; 128(1):38-43. PubMed ID: 15224019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic Peptide in patients with heart failure with versus without chronic kidney disease.
    Bruch C; Fischer C; Sindermann J; Stypmann J; Breithardt G; Gradaus R
    Am J Cardiol; 2008 Aug; 102(4):469-74. PubMed ID: 18678308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure.
    Fujimoto N; Onishi K; Sato A; Terasaki F; Tsukada B; Nozato T; Yamada T; Imanaka-Yoshida K; Yoshida T; Ito M; Hiroe M
    J Card Fail; 2009 Dec; 15(10):898-905. PubMed ID: 19944367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of BNP and cardiopulmonary exercise testing in patients with systolic heart failure on beta-blocker therapy].
    Pascual-Figal DA; Peñafiel P; Nicolas F; de la Morena G; Ansaldo P; Redondo B; Sánchez Mas J; Valdés M
    Rev Esp Cardiol; 2008 Mar; 61(3):260-8. PubMed ID: 18361899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern.
    Feola M; Aspromonte N; Milani L; Bobbio M; Bardellotto S; Barro S; Giovinazzo P; Noventa F; Valle R
    J Card Fail; 2008 Jun; 14(5):420-5. PubMed ID: 18514935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy.
    Komamura K; Sasaki T; Hanatani A; Kim J; Hashimura K; Ishida Y; Ohkaru Y; Asayama K; Tanaka T; Ogai A; Nakatani T; Kitamura S; Kangawa K; Miyatake K; Kitakaze M
    Heart; 2006 May; 92(5):615-8. PubMed ID: 16387818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of B-type natriuretic peptide levels before and after exercise and functional capacity in patients with idiopathic dilated cardiomyopathy.
    Pascual-Figal DA; Peñafiel P; de la Morena G; Redondo B; Nicolás F; Casas T; Valdés M
    Am J Cardiol; 2007 May; 99(9):1279-83. PubMed ID: 17478157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical course and risk profile in adolescents with idiopathic dilated cardiomyopathy.
    Limongelli G; Pacileo G; Ancona R; Eusebio G; D'Andrea A; Romano M; Di Salvo G; Rea A; Calabró P; Romano G; Maiello C; Calabró R
    Am J Cardiol; 2010 Mar; 105(5):716-20. PubMed ID: 20185022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric risk stratification in patients with mild to moderate chronic heart failure.
    Scardovi AB; De Maria R; Coletta C; Aspromonte N; Perna S; Cacciatore G; Parolini M; Ricci R; Ceci V
    J Card Fail; 2007 Aug; 13(6):445-51. PubMed ID: 17675058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.